Eli Lilly (LLY): FY25 Q2 earnings call, Aug 7, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Aug 7, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
21 matches for “Phase 3”; 5 quoted, at least 25 words apart.
…We delivered robust revenue growth, shared top line clinical data from multiple Phase III programs and invested in several initiatives that will support our future…
…such as blood pressure, cholesterol and inflammation. This is the second positive Phase III trial for orforglipron we reported this year, and we're encouraged by…
…positive European CHMP opinion for Kisunla. Announced positive results in the SURPASS-CVOT Phase III trial for tirzepatide in people with type 2 diabetes and heart…
…trends regarding time on therapy. We continue to generate additional data in Phase III trials that we believe will support an expanded label and use…
…last earnings call. During just the past 2 weeks, we shared 3 Phase III readouts from some of our most important molecules. I'll start with…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-08-07:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-08-07:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP